Previous 10 | Next 10 |
Esperion Therapeutics (NASDAQ:ESPR) is scheduled to announce Q1 earnings results on Tuesday, May 3rd, before market open. The consensus EPS Estimate is -$1.04 (+70.3% Y/Y) and the consensus Revenue Estimate is $15.41M (+92.6% Y/Y). Over the last 1 year, ESPR has beaten EPS estimates 25% of th...
ANN ARBOR, Mich., May 02, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from the CLEAR Harmony Open-Label Extension (OLE) Study of bempedoic acid, also known as NEXLETOL ® , in the American Journal of Cardiology . The paper, ...
ANN ARBOR, Mich., April 29, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10 th , 2022. ...
ANN ARBOR, Mich., April 25, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced support for a study to evaluate the effects of bempedoic acid and ezetimibe (NEXLIZET) on short-term LDL-cholesterol lowering in patients following a recent acute coronary syndrome (ACS) event. The ...
ANN ARBOR, Mich., April 19, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2022 financial results before the open of the U.S. financial markets on Tuesday, May 3, 2022. Following the release, company management will host a webcast and co...
ANN ARBOR, Mich., April 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from a pooled analysis of patients enrolled in four Phase 3 bempedoic acid studies in the Journal of Clinical Lipidology . The paper, “Efficacy and safety of...
ANN ARBOR, Mich., April 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL ® ) at the American College of Cardiology’s 71st Annual Scientific Session & Expo (ACC.22)....
ANN ARBOR, Mich., March 29, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming Needham 21 st Annual Healthcare Conference on Tuesday, April 12, 2022. Live audio webcasts of these e...
The commercial-stage pharma company, Esperion Therapeutics (NASDAQ:ESPR) announced on Tuesday that the company’s Chief Financial Officer Richard B. Bartram was stepping down from his positions effective April 08. In addition to his role as CFO, Bartram also functioned as principal fina...
Gainers: Incannex Healthcare Limited (NASDAQ:IXHL) +271%. Esperion Therapeutics (NASDAQ:ESPR) +10%. GitLab (NASDAQ:GTLB) +9%. Niu Technologies (NASDAQ:NIU) +7%. Lordstown Motors (NASDAQ:RIDE) +6%. Losers: Coupa Software Incorporated (NASDAQ:COUP) -29%. AnaptysB...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday. Shares of Argan, Inc. (NYSE:AGX) rose sharply during Friday's ...